Phase 2 · NCT07467447
GZBF
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Registry record
Trial details
- Trial
- GZBF
- ClinicalTrials.gov ID
- NCT07467447
- Indication
- Obesity
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- Hudson Biotech
- Enrolment
- 300
- Status
- Recruiting
- Interventions
- Drug: Retatrutide (LY3437943); Drug: Placebo; Behavioral: Standardized diet and physical activity counseling throughout the study.
- Comparator
- Placebo
- Eligible ages
- 18 Years – 75 Years
- Locations
- 1 site · China
- Study start
- 15 Feb 2026
- Primary completion
- 14 Mar 2027
- Study completion
- 17 Feb 2028
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 12 Mar 2026
Endpoints
Primary
Mean percent change in body weight from randomization/baseline to Week 24.
Secondary
Mean percent change in body weight from baseline to Week 48; Proportion of participants achieving ≥5%, ≥10%, and ≥15% body weight reduction at Weeks 24 and 48.; Mean change in body weight (kg) at Weeks 24 and 48.; Mean change in BMI (kg/m²) at Weeks 24 and 48.; Mean change in waist circumference (cm) at Weeks 24 and 48; Safety and tolerability outcomes (e.g., treatment-emergent adverse events; serious adverse events; discontinuations due to adverse events).